logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Breast Cancer Earlyonset

    FiltersReset Filters
    6 results

    • aromasin

      (exemestane)
      Pharmacia & Upjohn Company LLC
      Usage: AROMASIN is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after two to three years of tamoxifen, completing a total of five years of therapy. It is also used to treat advanced breast cancer in postmenopausal women progressing after tamoxifen.

    • kadcyla

      (ADO-TRASTUZUMAB EMTANSINE)
      Genentech, Inc.
      Usage: KADCYLA® is indicated for treating patients with HER2-positive metastatic breast cancer (MBC) who have received prior trastuzumab and a taxane, or those with early breast cancer (EBC) having residual invasive disease after neoadjuvant therapy. Patient selection is based on an FDA-approved diagnostic.

    • kisqali

      (ribociclib)
      Novartis Pharmaceuticals Corporation
      Usage: KISQALI is indicated for the adjuvant treatment of adults with HR-positive, HER2-negative early breast cancer at high risk of recurrence, and for advanced or metastatic HR-positive, HER2-negative breast cancer in combination with aromatase inhibitors or fulvestrant.

    • perjeta

      (Pertuzumab)
      Genentech, Inc.
      Usage: PERJETA is indicated for the treatment of HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel, and for early breast cancer in combination with trastuzumab and chemotherapy for neoadjuvant and adjuvant therapies, especially in high-risk patients.

    • phesgo

      (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
      Genentech, Inc.
      Usage: PHESGO is indicated for the neoadjuvant and adjuvant treatment of adults with HER2-positive early breast cancer, and for the treatment of adults with HER2-positive metastatic breast cancer in combination with docetaxel, specifically for those who have not received prior anti-HER2 therapy or chemotherapy.

    • verzenio

      (abemaciclib)
      Eli Lilly and Company
      Usage: VERZENIO (abemaciclib) is indicated for adults with HR-positive, HER2-negative breast cancer. It is used in combination with endocrine therapy for early breast cancer at high risk of recurrence and for advanced or metastatic cases, either with an aromatase inhibitor, fulvestrant, or as monotherapy after prior treatments.